Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(14 years from now) | |
US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(14 years from now) | |
US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
US10835499 | CORIUM | Systems and methods for long term transdermal administration |
May, 2038
(15 years from now) | |
US10966936 | CORIUM | Systems comprising a composite backing and methods for long term transdermal administration |
Aug, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM;TRANSDERMAL
33
United States
11
Japan
9
Korea, Republic of
7
Australia
6
Canada
6
China
6
European Union
3
Singapore
3
Russia
3
Mexico
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic